Wegovy savings programs in 2026: every legitimate way to pay less

The NovoCare savings card: $25/mo for commercially insured patients

If you have commercial health insurance and Wegovy is covered by your plan (even partially), the NovoCare savings card is the most powerful savings tool available. It caps your monthly out-of-pocket at $25 for Wegovy, regardless of your plan's stated copay or coinsurance — as long as you have qualifying commercial insurance. There is no income restriction for the savings card itself; the qualifier is your insurance type.

It cannot be used with Medicare, Medicaid, or any government-funded insurance program. That restriction is standard for manufacturer savings programs due to federal anti-kickback regulations. If you're on Medicare and were previously using the savings card, that eligibility ended when you transitioned.

• Who qualifies: commercially insured patients with Wegovy covered or partially covered by their plan.
• Who does not qualify: Medicare, Medicaid, CHIP, VA, or any other government insurance.
• How to get it: enroll through the NovoCare website or through a participating pharmacy at the point of sale.
• What to watch: the $25 cap applies per prescription fill, not per dose change. Confirm the current terms directly with NovoCare before relying on this figure.

Getting Wegovy covered by insurance: where to start

The savings card is only useful if your insurance covers Wegovy at all. Many plans do — and more have added coverage in 2025–2026 as the cardiovascular evidence for semaglutide (from the SELECT trial) has become harder to ignore. But coverage varies enormously by plan, employer, and whether the plan has specifically added an obesity treatment benefit.

• Check your plan's formulary: look for semaglutide or Wegovy under 'weight management' or 'obesity treatment,' not just the drug list.
• BMI and comorbidity criteria: most plans require a BMI of 30 or higher, or 27 or higher with at least one comorbidity (hypertension, high cholesterol, type 2 diabetes, sleep apnea, or cardiovascular disease).
• Prior authorization is almost always required: your prescribing doctor submits documentation of BMI, comorbidities, and often prior attempts at lifestyle modification.
• If denied: appeal with a physician letter citing clinical necessity and the SELECT trial data for cardiovascular benefit. Many denials reverse on the first appeal.
• Employer-sponsored plans: some large self-insured employers added GLP-1 obesity coverage in 2025–2026 even if their prior plans didn't include it — worth confirming with HR.

NovoCare self-pay: the best option for uninsured cash-pay patients

For women without insurance coverage for Wegovy, Novo Nordisk's NovoCare self-pay program is the lowest-cost brand-name pathway. The introductory rate starts at $199 a month; this typically transitions to an ongoing rate of $349 a month after the initial period. Both rates are for FDA-approved Wegovy, dispensed through the NovoCare pharmacy and shipped directly to you.

This bypasses retail pharmacies entirely and their associated markup. The $349 ongoing rate compares favorably to the $300–$500 range you'd pay at a retail pharmacy even with a GoodRx coupon, and it includes clinical support from the NovoCare system.

GoodRx coupons: better than retail, worse than NovoCare

GoodRx coupons for Wegovy typically bring the retail pharmacy price down to approximately $300–$500 a month, depending on the pharmacy, your location, and the dose. This is a meaningful discount from the $1,350 retail list price but is still more expensive than the NovoCare self-pay program for most patients. GoodRx coupons cannot be combined with insurance; you use one or the other.

GoodRx is worth checking if you've already filled a prescription at a retail pharmacy and want to know the best available cash price before paying. Pull prices for your specific dose and your local pharmacies — there can be significant variation between CVS, Costco, Walgreens, and independent pharmacies on the same coupon.

Medicare coverage for Wegovy: the SELECT trial changed things

Medicare's longstanding exclusion of obesity drugs from Part D coverage was the rule for years. The Inflation Reduction Act and the subsequent SELECT trial results shifted the picture for Wegovy specifically. The SELECT trial demonstrated that semaglutide reduced major cardiovascular events (heart attack, stroke, cardiovascular death) in patients with established cardiovascular disease — a benefit that Medicare's cardiovascular coverage can reach. As of 2026, Medicare Part D plans have begun to cover Wegovy for patients meeting the cardiovascular indication criteria. The specific copay depends on your plan and formulary tier.

If you're on Medicare and have a history of cardiovascular disease, it's worth asking your prescribing doctor to document this indication explicitly — it may be the path to coverage where pure obesity treatment would not qualify. Confirm current Medicare coverage status with your specific Part D plan before assuming.

What doesn't exist: free trials and patient assistance

Unlike some medications, Wegovy does not currently have a patient assistance program (PAP) for uninsured low-income patients. Novo Nordisk has faced significant criticism for this absence, given the drug's cost and the population that most needs it. The self-pay program at $349 a month is the lowest-cost option available for uninsured patients through official channels. For women who cannot afford even that rate, compounded semaglutide through a telehealth provider currently represents the only substantially cheaper alternative.